ArticleHeliyon2024
A new biomarker in the diagnosis and prognosis of pulmonary thromboembolism: Serum profilin-1.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Profilin and Non-Canonical Wnt Signaling: Coordinating Cytoskeletal Dynamics from Development to Disease.Journal of developmental biology · 2025Review
- Apelin-13 as a novel diagnostic laboratory biomarker in thromboembolic disorders: a review of literature with prospective insights.International journal of emergency medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pulmonary Thromboembolism (PTE) is one of the major cardiovascular diseases with high morbidity and mortality. Early diagnosis and accurate prognosis are essential in clinical management. This study aimed to investigate the efficacy of serum Profilin-1(PFN1) in diagnosing and prognosis PTE. Materials and methods: This study was conducted on patients older than 18 diagnosed with PTE and healthy volunteers with similar sociodemographic characteristics who applied to the emergency department between March 2022 and March 2023. Results: In the study, 102 patients diagnosed with PTE were in the patient group, and 64 healthy volunteers were in the control group. The median PFN1 level of the patient group was 2878 (124-5001) pg/mL, while the median PFN1 level of the control group was 579 (125-5001) pg/mL. The PFN1 level of the patient group was significantly higher than the control group (p < 0.001). PFN1 levels of 984.46 pg/mL and above had 76.47 % sensitivity and 79.69 % specificity in diagnosing PTE (AUC: 0.817; CI: 0.750-0.873; p < 0.0001). The median PFN1 level of patients with mortality was 5001 (1793.3-5001) pg/mL, while the median PFN1 level of patients without mortality was 1858 (124-5001) pg/mL. PFN1 levels of patients who developed mortality were significantly higher than those who did not develop mortality (p < 0.001). PFN1 levels of 3292.1 pg/mL and above had 90.91 % sensitivity and 71.25 % specificity in PTE prognosis (AUC: 0.861; CI: 0.778-0.921; p < 0.0001). Conclusion: Serum Profilin-1 levels are helpful as a diagnostic and prognostic indicator in PTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.